Biomedicines Free Full Text Detection Of Tert Promoter Mutations As Urothelial carcinoma (uc) is a common urological malignancy with a high rate of disease recurrence. telomerase activity, a hallmark of cancer characterized by overcoming the replicative senescence, is upregulated in over 90% of patients with uc. somatic mutations in the promoter region of telomerase reverse transcriptase (tert) are frequently. The tert promoter mutation and methylation or tert expression for uc prognosis. the evaluation of tert promoter mutations as a prognostic factor for uc survival gives rise to conflicting results . the association between the presence of tert promoter mutations and overall and or progression free survival (os and pfs) was shown in some studies.
Frontiers Clinical Application Of Tert Promoter Mutations In Kurtis b, zhuge j, ojaimi c, ye f, cai d, zhang d, et al. recurrent tert promoter mutations in urothelial carcinoma and potential clinical applications. ann diagn pathol. 2016;21:7–11. article. Progress is discussed in the progress in these areas and the challenges, clinical potential, and future direction for developing uc treatment methods are highlighted. urothelial carcinoma (uc) is a common urological malignancy with a high rate of disease recurrence. telomerase activity, a hallmark of cancer characterized by overcoming the replicative senescence, is upregulated in over 90% of. Mutations in the tert coding region are rare (frequency < 0.5%) 111, but tert promoter mutations occur in 60–80% of ucb samples, and the c228t and c250t mutations together account for 99% of. Clinical application of tert promoter mutations in urothelial carcinoma. urothelial carcinoma (uc) is a common urological malignancy with a high rate of disease recurrence. telomerase activity, a hallmark of cancer characterized by overcoming the replicative senescence, is upregulated in over 90% of patients with uc.
Frontiers Clinical Application Of Tert Promoter Mutations In Mutations in the tert coding region are rare (frequency < 0.5%) 111, but tert promoter mutations occur in 60–80% of ucb samples, and the c228t and c250t mutations together account for 99% of. Clinical application of tert promoter mutations in urothelial carcinoma. urothelial carcinoma (uc) is a common urological malignancy with a high rate of disease recurrence. telomerase activity, a hallmark of cancer characterized by overcoming the replicative senescence, is upregulated in over 90% of patients with uc. Recently, telomerase reverse transcriptase (tert) promoter mutation has been identified in thyroid cancer. it increases telomerase activity, which allows cancer cells to immortalize. it was found in 10 to 20% of differentiated thyroid carcinoma and 40% of dedifferentiated thyroid carcinoma. it is highly prevalent in old age, large tumor. 5. tert promoter mutations: novel prognostic factors in cancer patients. more and more studies have demonstrated a relevance of tert promoter mutations with clinic pathological characteristics in malignancies. we found that the presence of tert promoter mutations was significantly associated with metastases in thyroid and renal pelvic carcinomas .
Frontiers Clinical Application Of Tert Promoter Mutations In Recently, telomerase reverse transcriptase (tert) promoter mutation has been identified in thyroid cancer. it increases telomerase activity, which allows cancer cells to immortalize. it was found in 10 to 20% of differentiated thyroid carcinoma and 40% of dedifferentiated thyroid carcinoma. it is highly prevalent in old age, large tumor. 5. tert promoter mutations: novel prognostic factors in cancer patients. more and more studies have demonstrated a relevance of tert promoter mutations with clinic pathological characteristics in malignancies. we found that the presence of tert promoter mutations was significantly associated with metastases in thyroid and renal pelvic carcinomas .
Frontiers Tert Promoter Mutations And Methylation For Telomerase
Comments are closed.